We are a clinical-stage biotechnology company focused on engineering, developing, manufacturing, and ultimately commercializing a new generation of potent, ultra-long acting, scalable nutrient-stimulated hormone (NuSH) therapies for obesity and related diseases.

Jan 7, 2025 · Metsera is a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases. Metsera is advancing a broad portfolio of oral and injectable incretin, non-incretin and combination therapies with potential best-in-class profiles to address multiple therapeutic targets and meet the future ...

2 days ago · Metsera, an obesity drug developer, sold nearly 15.3 million shares at $18 apiece in an offering that ranks as one of the industry’s largest since 2022, according to BioPharma Dive data. Maze, a maker of kidney disease medicines, priced more than 8.7 million shares at $16 each, exceeding the terms it had set earlier this week.

Jan 7, 2025 · Months after posting weight loss of 7.5% at 36 days for patients taking MET-097i, Metsera releases mid-stage results of just over 11% average body weight reduction at 12 weeks, with no plateau and a promising safety profile.

1 day ago · New York City-based Metsera sold 15.28 million shares above its targeted range at $18 apiece. The company had initially marketed 17.19 million shares at a range of $15 to $17 each.

3 days ago · US-based Metsera has set its sights on a $289m public listing as the weight loss drug developer becomes one of the early biotechs to venture into the thawing IPO landscape in 2025. Metsera is offering over 17 million shares priced between $15 and $17 for its Nasdaq listing. The biotech is targeting $250.8m based on the midpoint of the price ...

Sep 24, 2024 · Recently debuted Metsera is unfolding some phase 1 data for its GLP-1 receptor agonist, revealing a 7.5% reduction in body weight compared to baseline at 36 days. While the biotech has yet to...

Apr 18, 2024 · Clinical-stage Metsera has emerged from stealth with $290 million in hand and the bold vision of ushering in the next generation of obesity and metabolic disease medicines. “It's an almost...

NEW YORK, April 18, 2024 -- (BUSINESS WIRE)--Metsera, Inc., a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases,...

Jan 7, 2025 · Privately-held biotechnology startup Metsera said Tuesday a long-acting GLP-1 shot it’s developing helped people who are overweight or have obesity lose more weight than placebo recipients in a Phase 2 trial.